Tyrosinase Activated Melanoma Prodrugs

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 7, 2009-09 ,pp. : 717-727

Bentham Science Publishers

Access to resources Recommend Favorite

Hypoxia-activated prodrugs in cancer therapy: progress to the clinic

By Denny William A  

Future Oncology, Vol. 6, Iss. 3, 2010-03 ,pp. : 419-428

Future Medicine

Access to resources Recommend Favorite

Editorial: Azoles in Anticancer Research: Rational Approaches, Design Strategies, Recent Insights and Future Perspectives

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 18, Iss. 1, 2018-03 ,pp. : 4-5

Bentham Science Publishers

Access to resources Recommend Favorite

Prospects for Hypoxia-Activated Anticancer Drugs

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 4, Iss. 5, 2004-09 ,pp. : 395-399

Bentham Science Publishers

Access to resources Recommend Favorite

Activated vitronectin as a target for anticancer therapy with human antibodies

By Bloemendal Haiko   Boer Hetty   Koop Elianne   Dongen Alice   Goldschmeding Roel   Landman Wil   Logtenberg Ton   Gebbink Martijn   Voest Emile  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 9, 2004-09 ,pp. : 799-808

Springer Publishing Company

Access to resources Recommend Favorite